BIOCRYST PHARMACEUTICALS INC (BCRX)
US09058V1035 - Common Stock
BCRX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. BCRX may be in some trouble as it scores bad on both profitability and health. BCRX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BCRX has reported negative net income.
In the past year BCRX has reported a negative cash flow from operations.
In the past 5 years BCRX always reported negative net income.
In the past 5 years BCRX always reported negative operating cash flow.
1.2 Ratios
BCRX has a better Return On Assets (-25.20%) than 72.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.2% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-40.02%
ROA(5y)-47.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BCRX's Gross Margin of 98.06% is amongst the best of the industry. BCRX outperforms 97.48% of its industry peers.
In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.
BCRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BCRX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BCRX has been increased compared to 5 years ago.
BCRX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -2.74, we must say that BCRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BCRX (-2.74) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.74 |
ROIC/WACCN/A
WACC9.44%
2.3 Liquidity
A Current Ratio of 2.78 indicates that BCRX has no problem at all paying its short term obligations.
The Current ratio of BCRX (2.78) is worse than 68.11% of its industry peers.
A Quick Ratio of 2.73 indicates that BCRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.73, BCRX is doing worse than 66.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.73 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 46.79% over the past year.
BCRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 29.92%.
The Revenue has been growing by 74.13% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.16%
Revenue 1Y (TTM)29.92%
Revenue growth 3Y165.04%
Revenue growth 5Y74.13%
Sales Q2Q%34.98%
3.2 Future
Based on estimates for the next years, BCRX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.48% on average per year.
BCRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.40% yearly.
EPS Next Y61.87%
EPS Next 2Y38.71%
EPS Next 3Y31.77%
EPS Next 5Y26.48%
Revenue Next Year36.8%
Revenue Next 2Y27.61%
Revenue Next 3Y23.24%
Revenue Next 5Y19.4%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as BCRX's earnings are expected to grow with 31.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.71%
EPS Next 3Y31.77%
5. Dividend
5.1 Amount
No dividends for BCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOCRYST PHARMACEUTICALS INC
NASDAQ:BCRX (1/6/2025, 5:50:11 PM)
After market: 7.87 +0.04 (+0.51%)7.83
+0.13 (+1.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners84.87%
Inst Owner Change0%
Ins Owners1.07%
Ins Owner Change16.92%
Market Cap1.62B
Analysts82.35
Price Target15.11 (92.98%)
Short Float %8.6%
Short Ratio8.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)29.87%
Min EPS beat(2)-6.5%
Max EPS beat(2)66.23%
EPS beat(4)2
Avg EPS beat(4)17.05%
Min EPS beat(4)-12.5%
Max EPS beat(4)66.23%
EPS beat(8)4
Avg EPS beat(8)-3.33%
EPS beat(12)7
Avg EPS beat(12)5.43%
EPS beat(16)8
Avg EPS beat(16)-0.33%
Revenue beat(2)2
Avg Revenue beat(2)5.53%
Min Revenue beat(2)2.03%
Max Revenue beat(2)9.02%
Revenue beat(4)4
Avg Revenue beat(4)4.76%
Min Revenue beat(4)1.74%
Max Revenue beat(4)9.02%
Revenue beat(8)5
Avg Revenue beat(8)1.88%
Revenue beat(12)5
Avg Revenue beat(12)0.26%
Revenue beat(16)8
Avg Revenue beat(16)6.95%
PT rev (1m)1.24%
PT rev (3m)2.52%
EPS NQ rev (1m)0%
EPS NQ rev (3m)41.28%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)0.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)19.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.93 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS1.99
BVpS-2.26
TBVpS-2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.2% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.06% | ||
| FCFM | N/A |
ROA(3y)-40.02%
ROA(5y)-47.36%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y0.21%
F-Score3
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 73.94% | ||
| Cap/Sales | 0.24% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.73 | ||
| Altman-Z | -2.74 |
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)177.05%
Cap/Depr(5y)129.28%
Cap/Sales(3y)0.89%
Cap/Sales(5y)1.25%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.16%
EPS Next Y61.87%
EPS Next 2Y38.71%
EPS Next 3Y31.77%
EPS Next 5Y26.48%
Revenue 1Y (TTM)29.92%
Revenue growth 3Y165.04%
Revenue growth 5Y74.13%
Sales Q2Q%34.98%
Revenue Next Year36.8%
Revenue Next 2Y27.61%
Revenue Next 3Y23.24%
Revenue Next 5Y19.4%
EBIT growth 1Y62.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year115.65%
EBIT Next 3Y50.03%
EBIT Next 5YN/A
FCF growth 1Y67.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.31%
OCF growth 3YN/A
OCF growth 5YN/A